Document Detail

Rational of the use of aliskiren in hypertension and beyond.
MedLine Citation:
PMID:  20019651     Owner:  NLM     Status:  MEDLINE    
Arterial hypertension is an independent risk factor for cardiovascular diseases and one of the major causes for mortality worldwide. Drugs, that control hypertension effectively are therefore needed to reduce hypertension induced morbidity and mortality. The inhibition of the renin-angiotensin-aldosterone-system (RAAS) is one target to control blood pressure in these patients. The new direct renin inhibitor aliskiren is one new substance on the market to inhibit the RAAS effectively by suppression of the plasma renin activity, which inhibits the RAAS at its rate-limiting step. Therefore, aliskiren in monotherapy and in combination might yield beneficial effects for the patients. Nevertheless, blood pressure lowering has to be combined with a reduction of target organ damage for all drug classes prescribed to patients with hypertension. Therefore, we review here the major effects of this new drug not only in regard to hypertension but also in regard to target organ damage reduction and possible changes in morbidity and mortality, which future trials will investigate.
D Westermann; K Savvatis; H P Schultheiss; C Tsch?pe
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  57     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-12-18     Completed Date:  2010-04-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  761-72     Citation Subset:  IM    
Department of Cardiology and Pneumology,Charit? School of Medicine, Campus Benjamin Franklin, Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amides / administration & dosage,  therapeutic use*
Angiotensin II / physiology
Angiotensin II Type 1 Receptor Blockers / administration & dosage,  therapeutic use
Antihypertensive Agents / administration & dosage,  therapeutic use*
Biphenyl Compounds / administration & dosage,  therapeutic use
Cardiovascular Diseases / mortality,  prevention & control*
Diabetic Nephropathies / drug therapy*
Diuretics / administration & dosage,  therapeutic use
Drug Therapy, Combination
Europe / epidemiology
Fumarates / administration & dosage,  therapeutic use*
Germany / epidemiology
Heart Failure / drug therapy*,  mortality
Hydrochlorothiazide / administration & dosage,  therapeutic use
Hypertension / blood,  drug therapy*,  epidemiology
Japan / epidemiology
Protein Precursors / physiology
Randomized Controlled Trials as Topic
Receptors, Cell Surface / physiology
Renin / antagonists & inhibitors*,  blood,  physiology
Renin-Angiotensin System* / drug effects,  physiology
Risk Factors
Tetrazoles / administration & dosage,  therapeutic use
Time Factors
World Health Organization
Reg. No./Substance:
0/Amides; 0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Diuretics; 0/Fumarates; 0/Protein Precursors; 0/Receptors, Cell Surface; 0/Tetrazoles; 0/aliskiren; 0/prorenin receptor; 11128-99-7/Angiotensin II; 138402-11-6/irbesartan; 58-93-5/Hydrochlorothiazide; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Use of the levonorgestrel-releasing intrauterine system: an Austrian perspective.
Next Document:  Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF ...